Cover Story
Conversation with The Cancer LetterFree
“The notion that cancer's not one disease, but thousands of diseases is really starting to sink in, and the implications of that fact are being felt throughout [NCI], and it means we have to change how we do everything. I hope that the early days of the Sharpless administration will be remembered as a time when we really bought into that reality and did some things differently,” NCI Director Norman “Ned” Sharpless said in a conversation with The Cancer Letter.
In Brief
Clinical Roundup
NCI Trials
NCI trials for February
NCI trials for FebruaryThe National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Radiation oncologist, global health expert C. Norman Coleman dies of sarcoma at 79
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- FDA’s Harpreet Singh: Overall survival data tells the full story of immune checkpoint inhibitor benefit in NSCLC
Pooled analysis finds correlations between early endpoints and OS in ICI trials - CMS starts paying for patient navigation; ACS offers navigation credentialing program
- Population scientist Monica Baskin is the “Jackie Robinson” of cancer center deputy directors
- Lillian Siu named 2024-2025 president-elect of AACR